In a randomized, open-label noninferiority trial of adults hospitalized for asthma exacerbation, an eosinophil-guided strategy for systemic corticosteroid duration was noninferior to fixed 5-day therapy for preventing treatment failure. Patients with noneosinophilic exacerbations received lower cumulative steroid exposure, with no differences in hospital length of stay, asthma control, recurrent exacerbations, or adverse events.

Source: Thorax